Pliant Therapeutics (PLRX)
(Delayed Data from NSDQ)
$12.88 USD
+0.15 (1.18%)
Updated May 28, 2024 04:00 PM ET
After-Market: $12.88 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PLRX 12.88 +0.15(1.18%)
Will PLRX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PLRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PLRX
Earnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to Decline
Is a Surprise Coming for Pliant Therapeutics (PLRX) This Earnings Season?
PLRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Biotech Stock Roundup: ICPT Up on Buyout Deal, IMVT & PLRX Gain on Study Data
Pliant (PLRX) Up on Success of Mid-Stage Liver Disease Study
Other News for PLRX
Piper Sandler Remains a Buy on Pliant Therapeutics (PLRX)
Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
Pliant Therapeutics management to meet with Piper Sandler
Commit To Purchase Pliant Therapeutics At $10, Earn 16% Using Options
Buy Rating for Pliant Therapeutics Backed by Promising Phase 2a Results of Bexotegrast in IPF Treatment